Omnicell (STU:OC9) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:OC9 Omnicell Inc STU:OC9
75 GF Score
Price €28.00
GF Value €33.42
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Omnicell Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Omnicell  (STU:OC9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Omnicell Cyclically Adjusted PS Ratio Related Terms


Omnicell Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Omnicell's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omnicell Cyclically Adjusted PS Ratio Chart

Omnicell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.01 2.45 1.70 1.88 1.65

Omnicell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.09 1.64 1.20 1.50

STU:OC9 vs SDGR, OMDA, CERT: Cyclically Adjusted PS Ratio Comparison

For the Health Information Services subindustry, Omnicell's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omnicell Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Omnicell's Cyclically Adjusted PS Ratio falls into.


STU:OC9
75GF Score
Omnicell Inc STU:OC9
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omnicell Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Omnicell's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Omnicell's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.799/333.9520*333.9520
=5.799

Current CPI (Jun. 2026) = 333.9520.

Omnicell Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.271 241.428 5.908
201612 4.281 241.432 5.922
201703 3.783 243.801 5.182
201706 4.288 244.955 5.846
201709 4.083 246.819 5.524
201712 4.340 246.524 5.879
201803 3.744 249.554 5.010
201806 3.959 251.989 5.247
201809 4.298 252.439 5.686
201812 4.475 251.233 5.948
201903 4.218 254.202 5.541
201906 4.506 256.143 5.875
201909 4.780 256.759 6.217
201912 5.176 256.974 6.726
202003 4.780 258.115 6.184
202006 4.249 257.797 5.504
202009 4.187 260.280 5.372
202012 4.751 260.474 6.091
202103 4.509 264.877 5.685
202106 4.806 271.696 5.907
202109 5.201 274.310 6.332
202112 5.459 278.802 6.539
202203 5.931 287.504 6.889
202206 6.722 296.311 7.576
202209 7.541 296.808 8.485
202212 6.536 296.797 7.354
202303 6.035 301.836 6.677
202306 6.041 305.109 6.612
202309 6.021 307.789 6.533
202312 5.292 306.746 5.761
202403 4.959 312.332 5.302
202406 5.585 314.175 5.937
202409 5.537 315.301 5.865
202412 6.140 315.605 6.497
202503 5.499 319.799 5.742
202506 5.456 322.561 5.649
202509 5.791 324.800 5.954
202512 6.000 324.054 6.183
202603 5.765 330.213 5.830
202606 5.799 333.952 5.799

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Omnicell (STU:OC9) Overvalued in 2026?

Based on GuruFocus' analysis, Omnicell stock appears to be undervalued. The current stock price of €28.00 is trading 16.2% below its estimated GF Value™ of €33.42. GuruFocus considers Omnicell to be Modestly Undervalued.

Key valuation signals for STU:OC9:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €33.42 vs. price of €28.00 (16.2% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the STU:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Omnicell Business Description

Address 4220 North Freeway, Fort Worth, TX, USA, 76137
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
75GF Score

Get the complete analysis for STU:OC9

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price
€33.42
GF Value